Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 1, 2016. The report serves as a notification to the market regarding the Company's total voting rights and capital structure in conformity with Disclosure and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a capital structure notification rather than a financial performance report.
Material Changes
The filing details the Company's issued share capital as of May 31, 2016:
- Total issued Ordinary Shares: 5,363,341,178 (25p each).
- Treasury Shares held: 491,505,950.
- Total voting rights: 4,871,835,228.
No material changes to financial performance or operational strategy are disclosed in this text.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the calculation of voting rights for shareholder notification purposes under the Financial Conduct Authority's rules.
Investor Verification Checklist
- Verify the total number of voting rights (4,871,835,228) against the latest annual report to confirm the denominator for disclosure thresholds.
- Confirm the number of shares held in Treasury (491,505,950) to assess potential buyback activity or capital management.
- Review the Company's Form 20-F for comprehensive financial metrics, as this 6-K does not contain performance data.